1 |
Liang J, Nishi H, Bian ML et al (2012) The ubiquitinconjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth. Oncol Rep 28, 1519-1525
DOI
|
2 |
Ayesha AK, Hyodo T, Asano E et al (2016) UBE2S is associated with malignant characteristics of breast cancer cells. Tumour Biol 37, 763-772
DOI
|
3 |
Jung CR, Hwang KS, Yoo J et al (2006) E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 12, 809-816
DOI
|
4 |
Li Z, Wang Y, Li Y et al (2018) Ube2s stabilizes beta-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development. Cell Death Dis 9, 456
DOI
|
5 |
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362, 2380-2388
DOI
|
6 |
Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13, 239-246
DOI
|
7 |
Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 12, 735-742
DOI
|
8 |
Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11, 121-128
DOI
|
9 |
Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15, 213-222
DOI
|
10 |
Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31, 3327-3334
DOI
|
11 |
Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371, 2167-2177
DOI
|
12 |
Dimova NV, Hathaway NA, Lee BH et al (2012) APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1. Nat Cell Biol 14, 168-176
DOI
|
13 |
Lin TH, Hsu WH, Tsai PH et al (2017) Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling. Food Funct 8, 1558-1568
DOI
|
14 |
Jemal A, Thomas A, Murray T and Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52, 23-47
DOI
|
15 |
Kirkpatrick DS, Hathaway NA, Hanna J et al (2006) Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. Nat Cell Biol 8, 700-710
DOI
|
16 |
Peters JM (2002) The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 9, 931-943
DOI
|
17 |
Ben-Eliezer I, Pomerantz Y, Galiani D, Nevo N and Dekel N (2015) Appropriate expression of Ube2C and Ube2S controls the progression of the first meiotic division. FASEB J 29, 4670-4681
DOI
|
18 |
Pan YH, Yang M, Liu LP, Wu DC, Li MY and Su SG (2018) UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma. Biochem Biophys Res Commun 503, 895-902
DOI
|
19 |
Yoshimura S, Kasamatsu A, Nakashima D et al (2017) UBE2S associated with OSCC proliferation by promotion of P21 degradation via the ubiquitin-proteasome system. Biochem Biophys Res Commun 485, 820-825
DOI
|
20 |
Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120
DOI
|
21 |
Yang Y, Guo J, Hao Y et al (2017) Silencing of karyopherin alpha2 inhibits cell growth and survival in human hepatocellular carcinoma. Oncotarget 8, 36289-36304
|
22 |
Wu T, Merbl Y, Huo Y, Gallop JL, Tzur A and Kirschner MW (2010) UBE2S drives elongation of K11-linked ubiquitin chains by the anaphase-promoting complex. Proc Natl Acad Sci U S A 107, 1355-1360
DOI
|
23 |
McGuire S (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7, 418-419
DOI
|
24 |
Alberg AJ, Brock MV, Ford JG, Samet JM and Spivack SD (2013) Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143, e1S-e29S
DOI
|
25 |
Paul A and Wang B (2017) RNF8- and Ube2S-Dependent Ubiquitin Lysine 11-Linkage Modification in Response to DNA Damage. Mol Cell 66, 458-472.e455
DOI
|
26 |
Garnett MJ, Mansfeld J, Godwin C et al (2009) UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit. Nat Cell Biol 11, 1363-1369
DOI
|
27 |
Bremm A, Freund SM and Komander D (2010) Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne. Nat Struct Mol Biol 17, 939-947
DOI
|
28 |
Penas C, Ramachandran V and Ayad NG (2011) The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Front Oncol 1, 60
|
29 |
Chen MF, Lee KD, Lu MS et al (2009) The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma. J Mol Med (Berl) 87, 307-320
DOI
|
30 |
Roos FC, Evans AJ, Brenner W et al (2011) Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma. Am J Pathol 178, 853-860
DOI
|